Wangli Tech Becomes First Chinese Mental Health Digital Therapeutics Company to Join Digital Therapeutics Alliance (DTA)

2021 was hailed by the industry as “Year One of Digital Therapeutics in China.” In recent years, digital therapeutics (DTx) have continued to attract increasing attention from the industry.

In late June, Wangli Technology officially received certification from the Digital Therapeutics Alliance (DTA), becoming the first psychiatric digital therapeutics company in China to be certified as a member enterprise by the alliance.

This not only demonstrates that Wangli Technology has gained recognition from globally authoritative industry organizations and peers in the field of digital healthcare, but also brings the most advanced international theoretical academic guidance and practical experience for building an innovative business model and promoting win-win development for doctors and patients.

According to the DTA official website, due to the stringent review process, only more than 50 companies worldwide have obtained certification to date, including global digital therapeutics industry leaders such as Pear Therapeutics and Akili Interactive Labs. Wangli Technology successfully obtained certification after undergoing academic review, which is of significant importance. This indicates that the international digital therapeutics industry has begun to recognize various aspects of domestic digital therapeutics platforms represented by Wangli Technology, including their business models, technical capabilities, and academic strengths.

The Digital Therapeutics Alliance (DTA), established in 2017, is a non-profit industry consortium composed of global leaders in the digital therapeutics sector, including digital therapeutics companies, universities, and research institutions. The alliance aims to improve clinical and health economic outcomes and enhance global healthcare standards by promoting the development of digital therapeutics. Its primary mission is to increase understanding, adoption, and integration of digital therapeutics among patients, clinicians, payers, and policymakers through education, advocacy, and cross-industry collaboration. Membership in this organization primarily facilitates academic exchange among digital therapeutics companies within the industry and does not involve business operations, technology, or data sharing.

According to the official definition by the Digital Therapeutics Alliance (DTA), digital therapeutics (DTx) are evidence-based therapeutic interventions driven by software programs to prevent, manage, or treat a medical disorder or disease. DTx can be used independently or in combination with medications, devices, or other therapies. Internationally, common DTx products include software or software-hardware combinations whose safety and efficacy have been validated through clinical trials. Unlike traditional pharmaceuticals, DTx offers greater safety and accessibility, as patients can access these interventions via smartphones. DTx can be applied across multiple scenarios, including disease assessment, treatment, prevention, and out-of-hospital management. By targeting specific disease areas and patient populations, DTx provides personalized intervention plans, improves patient adherence, and thereby achieves better therapeutic outcomes. Empowered by big data and AI algorithms, DTx can continuously upgrade and iterate to enhance its “therapeutic efficacy,” ultimately leading to improved patient prognoses.

Digital therapeutics products offer the following value:

● Optimize clinical and health economic outcomes

● Provide high-quality treatment to underserved populations

● Easily expanded and used via patients’ own devices

● Patients can use it at home

● Transforming how patients understand, manage, and engage with healthcare

● Expands clinicians’ capacity to care for patients

● Support medical teams in environments with varying levels of healthcare infrastructure

● Reduce overall care costs

In 2020, digital healthcare entered a fast lane of development. The characteristics of the mental health field are particularly well-suited for the application and promotion of digital therapeutics (DTx). The most significant value of DTx lies in its ability to directly improve disease symptoms. Adhering to scientific rigor, Wangli Technology has explored and implemented DTx solutions across multiple areas, including addiction and depression, achieving internationally leading results. Joining the Digital Therapeutics Alliance (DTA) not only signifies recognition of Wangli Technology’s achievements but also reflects our commitment to leveraging industry-wide collaboration to accelerate the treatment and improvement of diseases.

Focusing on mental disorders and adhering to a development strategy centered on multi-pipeline R&D and multi-scenario accessibility, Wangli Technology has truly realized a data-driven, patient-centric approach. In the future, Wangli Technology will further advance its value proposition—centered on patient benefits, guided by value-based healthcare, and supported by medical evidence—to create an integrated psychiatric management solution based on digital therapeutics. Leveraging its proprietary big data platform and artificial intelligence capabilities, the company will provide data-driven assessment and intervention products that are continuously upgraded and iterated through technology and product innovation. This will ultimately deliver accurate and timely out-of-hospital therapeutic interventions and refined management for users. With the mission of “exploring the human brain,” Wangli Technology is committed to enhancing patients’ survival benefits and quality of life.